a:5:{s:8:"template";s:9184:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<meta content="text/html; charset=utf-8" http-equiv="content-type"/>
<meta content="IE=edge" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Roboto+Condensed%3A300%2C300i%2C400%2C400i%2C600%2C600i%2C800%2C800i&amp;subset=latin%2Clatin-ext" id="bulk-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}p.has-drop-cap:not(:focus)::first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}p.has-drop-cap:not(:focus)::after{content:"";display:table;clear:both;padding-top:14px} @font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:300;src:local('Roboto Condensed Light Italic'),local('RobotoCondensed-LightItalic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVg2ZhZI2eCN5jzbjEETS9weq8-19eDpCEoY9Nc.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:400;src:local('Roboto Condensed Italic'),local('RobotoCondensed-Italic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVj2ZhZI2eCN5jzbjEETS9weq8-19eLAQM4.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:300;src:local('Roboto Condensed Light'),local('RobotoCondensed-Light'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVi2ZhZI2eCN5jzbjEETS9weq8-33mZGCoYag.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:400;src:local('Roboto Condensed'),local('RobotoCondensed-Regular'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVl2ZhZI2eCN5jzbjEETS9weq8-19y7CA.ttf) format('truetype')} /*! normalize.css v3.0.3 | MIT License | github.com/necolas/normalize.css */html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}.text-center{text-align:center}ul{margin-top:0;margin-bottom:10px}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-brand{float:left;padding:15px 15px;font-size:18px;line-height:20px;height:50px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}@media (min-width:768px){.navbar-right{float:right!important;margin-right:-15px}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{content:" ";display:table}.container-fluid:after,.container:after,.nav:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}body,html{overflow-x:hidden}body{font-family:'Roboto Condensed',"Helvetica Neue",helvetica,arial,sans-serif;padding:0;color:#404040;font-weight:400;line-height:1.8;font-size:16px;word-wrap:break-word;overflow-x:hidden}a,a:active,a:focus,a:hover{text-decoration:none;color:#0090ff}ul{padding-left:20px}a:active{border-bottom:none}.page-area{padding-top:70px}@media (min-width:768px){.navbar-nav>li>a{padding-top:25px;padding-bottom:25px;transition:all .5s ease-in-out;-moz-transition:all .5s ease-in-out;-webkit-transition:all .5s ease-in-out;-o-transition:all .5s ease-in-out}#site-navigation .container{padding-left:0;padding-right:0}}@media (max-width:767px){.navbar-nav a:focus,.navbar-nav a:hover{color:#fff!important;background-color:#000!important}.menu-container{width:70%;position:absolute;left:0;height:100vh;transform:translate3d(-100%,0,0);overflow-y:auto;overflow-x:auto;background-color:#fff;top:100%}.navbar-brand{padding-right:55px!important}.page-area{left:0;transform:translate3d(0,0,0);transition:transform .5s ease}.navbar-nav{padding:0;margin:0}.navbar-nav a{font-size:14px;padding:12px 10px!important;margin:0!important;line-height:16px!important;float:left!important;margin:0!important;width:100%;text-transform:none!important;word-wrap:break-word;white-space:normal!important}.navbar-nav li{padding:0!important;margin:0!important}}#site-navigation{min-height:70px}.navbar-nav>li>a{border-bottom:0;text-transform:uppercase}.site-title{margin:0;padding:0;font-size:22px;line-height:28px}p.site-description{font-size:13px;line-height:18px;margin:0;-webkit-transition:all .5s ease;transition:all .5s ease}.site-branding-logo{float:left}.site-branding-logo a{border:none;z-index:9999;position:relative}.navbar-brand{padding:10px 15px;height:auto;z-index:99999;position:relative;z-index:1}.navbar{margin-bottom:0}.main-menu{position:relative}.navbar-fixed-top{position:absolute}#site-navigation{background-color:#fff;-webkit-box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);border:none}#site-navigation,nav a{-webkit-transition:all .3s ease;transition:all .3s ease;color:#000}.footer-credits{border-top:1px solid #ccc;padding:15px;clear:both;margin-top:20px;background-color:#fff}</style>
 </head>
<body class="wp-custom-logo" id="blog">
<div class="main-menu">
<nav class="navbar navbar-default navbar-fixed-top" id="site-navigation">
<div class="container">
<div class="navbar-header">
<div class="site-header">
<div class="site-branding-logo">
<a class="custom-logo-link" href="#" itemprop="url" rel="home"></a> </div>
<div class="site-branding-text navbar-brand">
<p class="site-title"><a href="#" rel="home">{{ keyword }}</a></p>
<p class="site-description">
{{ keyword }}</p>
</div>
</div>
</div>
<div class="menu-container"><ul class="nav navbar-nav navbar-right" id="menu-menu-1"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-72 dropdown" id="menu-item-72"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="Projects">Projects</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-73 dropdown" id="menu-item-73"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="About">About</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-74" id="menu-item-74"><a href="#" title="Contacts">Contacts</a></li>
</ul></div> </div>
</nav>
</div>
<div class="page-area">	
{{ text }}
<br>
<br>
{{ links }}
</div>
<footer class="footer-credits container-fluid row" id="colophon">
<div class="container">
<p class="footer-credits-text text-center">{{ keyword }} 2020</p>
</div>
</footer>
</body>
</html>";s:4:"text";s:7257:"FOSAPREPITANT DIMEGLUMINE: FOSAPREPITANT DIMEGLUMINE: EQ 150MG BASE/VIAL: POWDER;INTRAVENOUS: Prescription: AP: No: No: Approval Date(s) and History, Letters, Labels, Reviews for ANDA 212957. /SM 0.02 h�b``�a``�``e`H4ab@ !�(��>����`r?��c~�/��f�i�{E0���v� Rl��i9 ���30���,`.e	b�bIfY�r���c?s�cS�3��zN1.eJe8��ɨ`t���Ԇ�X��
�l���4#Ei�#��4��J�/�؞߆�b� Ketoconazole: When a single 125-mg dose of oral aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold [see Drug Interactions (7.2)]. Hypersensitivity Reactions (including anaphylaxis and anaphylactic shock): May occur during or soon after infusion. Fosaprepitant for Injection is contraindicated in patients with known hypersensitivity to any component of this drug and concurrent use with pimozide. Original Approvals or Tentative Approvals. Death of skin tissue (necrosis) has happened in some people getting this type of chemotherapy medicine. Fresenius Kabi is a leading developer and supplier of generic injectable medicines used in the treatment of cancer helping to make oncology therapies more affordable and accessible. 90 0 obj
<>
endobj
               
 Do not receive fosaprepitant for injection if you: What should I tell my healthcare provider before receiving fosaprepitant for injection? This Important Safety Information does not include all the information needed to use Fosaprepitant for Injection safely and effectively. Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of fosaprepitant for injection, 150 mg intravenously over 20 to 30 minutes approximately 30 minutes prior to chemotherapy. Patient demographics were similar between the two treatment groups. endstream
endobj
91 0 obj
<>
endobj
92 0 obj
<>
endobj
93 0 obj
<>stream
 *Fosaprepitant for injection placebo and dexamethasone placebo (on Day 1) were used to maintain blinding. How will I receive fosaprepitant for injection? Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Fosaprepitant for Injection is contraindicated in patients with known hypersensitivity to any component of this drug and concurrent use with pimozide. Inhibition of CYP3A4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide. acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. Aprepitant and fosaprepitant were not genotoxic in the Ames test, the human lymphoblastoid cell (TK6) mutagenesis test, the rat hepatocyte DNA strand break test, the Chinese hamster ovary (CHO) cell chromosome aberration test and the mouse micronucleus test. LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Fosaprepitant for Injection 150 mg per vial, the newest addition to the company’s generic oncology portfolio. Do not reinitiate Fosaprepitant for Injection if symptoms occur with previous use. Discontinue infusion and administer treatment if a severe reaction develops. TALLman Labeling. At Fresenius Kabi, we have a singular purpose – to put lifesaving medicines and technologies in the hands of healthcare professionals and to find answers to the challenges they face. Animal and human studies have shown that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis. Aprepitant after Fosaprepitant Administration. Fosaprepitant for Injection is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: Limitations of use: Fosaprepitant for Injection has not been studied for treatment of established nausea and vomiting. Most ISR can happen with the first, second, or third dose and some can last up to 2 weeks or longer. P-glycoprotein substrates: Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of oral aprepitant with digoxin in a clinical drug interaction study. Refer to the ondansetron prescribing information for the current recommended dose. Fosaprepitant is metabolized in various extrahepatic tissues; therefore hepatic impairment is not expected to alter the conversion of fosaprepitant to aprepitant. What are the ingredients in fosaprepitant for injection? acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. Most common adverse reactions in adults (≥2%) are: fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity.                 Biochemical Data Summary. These differences are not considered clinically meaningful. (, Most common adverse reactions in adults (≥ 2%) are: fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity. Fresenius Kabi is a leading developer and supplier of generic injectable medicines used in the treatment of cancer helping to make oncology therapies more affordable and accessible. See full prescribing information for FOSAPREPITANT FOR INJECTION. This recall is being performed to the user level. Discontinue infusion and administer treatment if a severe reaction develops. The company’s global headquarters is in Bad Homburg, Germany. Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. If symptoms occur, discontinue the drug. Please see the full prescribing information for Fosaprepitant for Injection at https://tinyurl.com/yjhz4l42. Warfarin (a CYP2C9 substrate): Risk of decreased INR of prothrombin time; monitor INR in 2−week period, particularly at 7 to 10 days, following initiation of Fosaprepitant for Injection.                                                     Labels, All Index These differences are not considered clinically meaningful [see Use in Specific Populations (8.5)]. “Fresenius Kabi is pleased to continue the expansion of one of the most comprehensive generic oncology portfolios in the United States by offering Fosaprepitant for Injection,” said John Ducker, president and CEO of Fresenius Kabi USA. /BitsPerComponent 8 In healthy young adults, aprepitant accounts for approximately 24% of the radioactivity in plasma over 72 hours following a single oral 300-mg dose of [14C]-aprepitant, indicating a substantial presence of metabolites in the plasma. ";s:7:"keyword";s:28:"fresenius kabi fosaprepitant";s:5:"links";s:954:"<a href="http://newdestinychurchpc.com/blog/article.php?tag=muhammad-ali-quotes-on-love-6bb478">Muhammad Ali Quotes On Love</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=top-chip-brands-6bb478">Top Chip Brands</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=danny-trevathan-extension-6bb478">Danny Trevathan Extension</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=hmrc-jobs-6bb478">Hmrc Jobs</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=edge-of-seventeen-ukulele-chords-6bb478">Edge Of Seventeen Ukulele Chords</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=complaint-antonym-6bb478">Complaint Antonym</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=uscis-juvenile-record-6bb478">Uscis Juvenile Record</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=is-kieran-tierney-playing-today-6bb478">Is Kieran Tierney Playing Today</a>,
";s:7:"expired";i:-1;}